INTRODUCTION
A phosphorylated sulfhydryl compound, S-2-[3-aminopropylamino]ethylphosphoro thioic acid (WR-2721), has shown a high degree of protection of normal tissues against whole body radiation exposure while affording barely detectable protection to tumors in experimental systems'-".
Since this compound has been shown to be less toxic than other radioprotectants", this drug is expected to have a potential value in the radio therapy of tumors in humans. Apffel et al." have shown that radioprotective thiols and thiophosphates including WR-2721, without radiation exposure, have an ability to bring about the inhibition of growth of solid tumors in experimental animals, when these drugs were applied to the host animals daily. They suggested that this fact may open new avenues toward chemotherapy and perhaps chemoprophylaxis of neoplastic diseases. Present study was undertaken to examine the effects of the daily treatment with WR-2721 on Ehrlich's ascites tumor-bearing mice. The data obtained showed that the drug suppresses the growth of ascites tumor cells but causes earlier death of tumor-bearing mice.
MATERIALS AND METHODS
ICR/JCL female mice (purchased from CLEA Japan, Osaka, Japan) were used throughout this experiment.
Mice were seven-week-old at the start of experiment. They were separated into six experimental groups. Groups 1-3 were subjected to the daily Z*. p. administration of the drug alone, at doses of 0, 1 and 5 mg/day/mouse, respectively.
Mice of groups 4-6 were inoculated Z. p. with Ehrlich's ascites tumor cells and then injected daily with WR-2721 at the doses of 0, 1 and 5 mg/day/mouse, respectively. These mice were housed in plastic cages. They were maintained at 25±1°C under illumination condition of 14 hr of light and 10 hr of dark and were fed F-2 diet (Funahashi Farms, Funahashi, Japan) and given water ad libitumn.
A strain of Ehrlich's ascites tumor cells, LP-12, was kindly supplied from Dr. T. Tanaka (Kansai Medical College, Moriguchi, Japan). The cells were routinely maintained in ICR/JCL female mice by inoculation of ascitic fluid into fresh mice at 8-10 day intervals. Mice of groups 4, 5 and 6 were inoculated Z'. p. with ascites tumor cell suspension (5x101 cells/0.3 ml). The cell suspension was prepared by counting the cell number with hemocytometer and by diluting ascitic fluid with sterilized saline.
WR-2721 (supplied from Yamanouchi Pharmaceutical Co. Ltd., Tokyo) was dissolved in sterilized saline to obtain concentrations of 10 mg/ml or 50 mg/ml. All mice, both tumor-cell inoculated (groups 4-6) and non-inoculated (groups 1-3), were injected Z'. P., daily with 0.1 ml of the WR-2721 solution or saline, from the day of inoculation (1 to 2 hr after inoculation).
The doses injected were 0 (groups 1 and 4), 1 (groups 2 and 5) and 5 (groups 3 and 6) mg/day/mouse.
The day of ascites tumor cell inoculation and start of WR-2721 injection was referred to Day 0 of the experiment.
The treat ment was continued up to Day 22, when almost all of the inoculated mice died.
The mice in six groups (50 mice/inoculated group ; 30 mice/non-inoculated group) were checked every day for their death, in order to obtain time-survival curves to WR-2721 daily treatment for six groups of mice. Twenty mice in each group were marked and serially weighed during treatment period. In groups 4-6, the mice which died during treatment period were weighed within 24 hr after death.
In another series of experiments, on Days 6, 8 and 13, inoculated mice (5 mice/ group with the exception of 3 mice in group 6 on Day 13) were sacrificed and dissected, and ascitic fluid was sucked with a pipette. Abdominal cavity was washed once with 2 ml of saline. The fluid and the saline for washing were combined to measure the volume of fluid. Volume of ascitic fluid per mouse was calculated by subtracting 2 ml from the measured volume. The fluid was then diluted with saline and the number of cells was determined using a type D Coulter counter under setting conditions of aperture current 1 and discrimination 5. Red blood cells (less than 5 pm in diameter) were excluded from counting, since under these conditions the cells less than 7 ,um in diameter were not scored.
The proportion of host nucleated cells to the nucleated ascitic cells was checked by microscopic observations.
On Days 4, 6, 8, 11 and 13, ascitic cells were sampled and smeared on slide glass. Sampling was made by sacrificing and dissecting mice on Days 4 and 13, and by using disposable syringe from living mice on Days 6, 8 and 11. The cells were fixed with methanol and stained with Giemsa. For each sample, cell count was done in such a way that the number of Ehrlich's tumor cells exceeds 200. Diameters of living cells were measured microscopically using a micrometer. The statistical significance of difference between treated and control samples was tested using t-test with Cochran-Cox approximation.
RESULTS AND DISCUSSION
Toxic effect of WR-2721 was examined by daily injection into tumor-bearing mice and non-inoculated mice. In non-inoculated groups, no mouse died during the experi mental period, while most of the inoculated mice died (Fig. 1) . It was found in the inoculated groups that the mean survival period in 5 mg treated mice (13 days) was 3 days shorter than that of 0 or 1 mg treated mice (16 days). These results indicate that daily treatment with 5 mg WR-2721 is toxic to tumor-bearing mice but not to non-inoculated mice, so far as the toxicity was judged from survival.
Changes in body weight of six groups of mice during daily treatment period were diagrammed in Fig. 2 . No distinct changes in body weight could be found among three non-inoculated groups (groups 1-3), although body weight of 5 mg injected mice (group 3) seemed to decrease slightly.
In inoculated groups, in contrast, body weight increased rapidly during early period of experiment.
Later, the body weight in two groups (groups 4 and 6) seemed to reach a plateau. The level of plateau for 5 mg treated group (group 6) was lower than that for saline injected control (group 4). Body weight of 1 mg treated mice (group 5) increased consistently and reached a similar level to that of saline injected group (group 4). Body weight of dead mice was also measured in the inoculated groups of mice. As can be seen in Table 1 , average body weight at death was significantly different between 5 mg treated and saline treated mice : Five mg treated mice were lighter than O mg treated mice when they died. Treatment with 1 mg gave a similar weight to that for saline treated mice. These findings indicated that increase in body weight of tumor-bearing mice was reduced by the daily administration of 5 mg of the drug.
It was supposed that changes in body weight may reflect the growth of tumor. Change in body weight was used as a indicator of the effect of drugs on tumor growth"'.
Thus, above-mentioned observations on body weight suggest that daily injection with 5 mg, but not 1 mg, of WR-2721 to mice suppresses the growth of ascitic cells. This idea was tested by the examination for the mode of increase during daily injection period in the volume of ascites and in the number of ascitic cells per inoculated mouse (groups 4-6). Table 2 shows that the volume of ascitic fluid in saline injected group increased steadily during daily treatment period. In 5 mg treated groups, such a increase was suppressed, and the fluid volume remained smaller than that in control. One mg treated mice showed a response pattern similar to the control. As shown in a) 95% confidence limits. *** Significant at the 0 .1% level from saline treated mice. Table 2 Effect of daily injection with WR-2721 on the volume of ascitic fluid in the inoculated mouse.
a) 95% confidence limits. * Significant at the 5% level from saline treated mice . ** Significant at the 1% level from saline treated mice . Nucleated non-tumor cells such as leucocytes were found micro scopically to be larger than 7,um in diameter.
Such cells were counted, as well as tumor cells (15-20,um in diameter), by Coulter counter, while red blood cells (less than 5 ,um in diameter) were excluded from counting. Thus, the figures in Table 3 (column 3) should be corrected, in order to assess the effect of WR-2721 on ascites tumor cells.
The proportion of nucleated non-tumor cells to ascitic nucleated cells were micro scopically examined on Days 4, 6, 8, 11 and 13 (Data were shown for Days 6, 8 and 13 in Table 3 , column 4). Percentage of non-tumor cells in control samples increased rapidly 6-8 days after inoculation with ascitic cells, and reached to a level of about 15% (16.4±2.4% on day 11). In the case of 5 mg treated samples, rapid increase in the proportion of non-tumor cells was observed between 8 and 11 days (13.2±6.4%) after inoculation, indicating that daily application of 5 mg WR-2721 delayed the onset of their increase. Being based on microscopic observation on the proportion of nucleated non-tumor cells to ascitic nucleated cells, the numbers of host nucleated cells and ascites tumor cells were calculated (columns 5 and 6 of Table 3 ). Daily application of WR-2721 reduced the number of host nucleated cells (column 5). The number of ascites tumor cells was larger in O mg treated mice than in 5 mg treated mice (column 6). It can be, thus, concluded that daily application of WR-2721 suppressed the growth of not only tumor cells but also host nucleated cells. It remains to be resolved why application of the drug caused earlier death of tumor-bearing mice irrespective of its suppression of the growth of tumor cells. Two hypotheses can be made to explain this finding. First, daily application of WR-2721 may reduce a tolerance capacity of mice to the toxic effect of tumor growth, by damaging a biologically important system for the tolerance.
In this context, it should be noted that the decrease in the number of host nucleated cells by WR-2721 (Table 3 , column 5) might play a major role in reducing the tolerance capacity.
Second, WR-2721 may be converted to a more toxic substance by reacting directly or indirectly with ascites tumor cells.
The finding of earlier death of tumor-bearing mice by WR-2721 injection may indicate that the present procedure of drug administration is not applicable to chemo therapy and chemoprophylaxis of neoplastic diseases. Furthermore, it might be suggested from our results that cautions should be exercised to radiotherapy of human cancers if each fractionated radiation dose is preceeded by administration of radioprotector such as WR-2721, although further animal experiments about radiation effects on our systems are clearly necessitated.
